Curated News
By: NewsRamp Editorial Staff
May 14, 2025
Annovis Bio Commences Phase 3 Trial for Alzheimer's Treatment
TLDR
- Annovis Bio (NYSE: ANVS) initiated Phase 3 trial in early Alzheimer’s, aiming to assess buntanetap's effects with 760 participants, giving a competitive edge in neurodegenerative research.
- Annovis Bio's Phase 3 trial for buntanetap in early Alzheimer’s evaluates symptomatic and disease-modifying effects over 18 months with enrollment of up to 760 participants.
- Annovis Bio's innovative therapies targeting neurotoxic proteins in Alzheimer’s and Parkinson’s aim to restore brain function, improving patients' quality of life, making tomorrow better.
- Annovis Bio's participation in key conferences and securing a new U.S. patent for buntanetap shows promising advancements in neurodegenerative treatment, worth keeping an eye on.
Impact - Why it Matters
This news matters as it highlights the progress made by Annovis Bio in developing innovative therapies for neurodegenerative diseases like Alzheimer's and Parkinson's. The initiation of the Phase 3 trial signifies a significant step towards potentially addressing the unmet medical needs in these conditions, offering hope for improved brain function and quality of life for patients.
Summary
Annovis Bio (NYSE: ANVS) initiated its pivotal Phase 3 clinical trial in early Alzheimer’s disease during Q1 2025, with enrollment now underway for up to 760 participants to assess buntanetap’s symptomatic and disease-modifying effects over 18 months. The company also secured a new U.S. patent for buntanetap and participated in several key scientific and investor conferences. Cash and equivalents rose to $22.2 million as of March 31, 2025, while R&D expenses fell year-over-year to $5.0 million.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Annovis Bio Commences Phase 3 Trial for Alzheimer's Treatment
